AlloVir, Inc. (ALVR)
| Market Cap | 674.50M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -188.52M |
| Shares Out | 84.95M |
| EPS (ttm) | -2.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,392 |
| Open | 7.25 |
| Previous Close | 7.24 |
| Day's Range | 6.8 - 7.33 |
| 52-Week Range | 3.17 - 19.08 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 26.78 (+292.1%) |
| Earnings Date | Nov 4, 2022 |
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenz... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ALVR stock is "Buy." The 12-month stock price forecast is 26.78, which is an increase of 292.09% from the latest price.
News
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p...
Final Data from AlloVir's Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentati...
WALTHAM, Mass.
Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 259.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will par...
Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect?
The consensus price target hints at a 251.2% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...
AlloVir Reports Second Quarter 2022 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the second quarter en...
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 447% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy...
AlloVir Announces $126.6 Million Registered Direct Offering
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purchase agreement wit...
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of p...
AlloVir Reports First Quarter 2022 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter end...
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.
Why Is AlloVir (ALVR) Stock Up 30% Today?
AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel. The post Why Is AlloVir (ALVR) Stock Up 30% Today?
Why AlloVir Stock Is Surging Today
AlloVir Inc (NASDAQ: ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its lead in...
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multip...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regen...
AlloVir Appoints Shawn Tomasello to Its Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. ...
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infectio...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an...
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participa...
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, ...
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Ade...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus...
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present a...
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially lea...
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 6...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 ...
AlloVir to Host Virtual Investor Event
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST....